Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâre developing a new type of targeted therapy that ââŚrelies on knowledge from an RNA-based diagnostic instead of more traditional DNA-based diagnostics to determine if a patient with cancer is a candidate for our targeted therapy.â They believe that this type of diagnostic will help unlock targeted therapies for the 70% of cancer patients who do not have âdruggableâ genetic mutations in their DNA. So far, Nemucore has raised $7M from foundation grants and the National Cancer Institute; they have over 57 investors; and leading experts at Memorial Sloan Kettering and Moffitt Cancer Centers are set to perform their clinical trial. Plus, their leadership team has over 100 years of biopharmaceutical experience. The bottom line? Nemucore wants, with this campaign, to âcure AML together and open a new future of cancer care.â Source
No articles found.
As a leading provider of innovative technologies for the treatment of Atrial Fibri...
As a leading provider of innovative technologie...
Equillium is a biotechnology company leveraging deep understanding of immunobiolog...
Equillium is a biotechnology company leveraging...
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed st...
Momenta Pharmaceuticals is a biotechnology comp...
UNITY Biotechnology is developing therapeutics to extend human healthspan by slowi...
UNITY Biotechnology is developing therapeutics ...
At PRA Health Sciences, we work side-by-side with our clients, to move drug discov...
At PRA Health Sciences, we work side-by-side wi...
Neos Therapeutics develops, manufactures, and commercializes innovative extended-r...
Neos Therapeutics develops, manufactures, and c...
Kazia Therapeutics is an oncology-focused biotechnology company, developing innova...
Kazia Therapeutics is an oncology-focused biote...
Join the National Investor Network and get the latest information with your interests in mind.